Generic Name and Formulations:
Sotalol HCl 5mg/mL; oral soln; grape flavor.
Arbor Pharmaceuticals, LLC
Indications for SOTYLIZE:
Documented life-threatening ventricular arrhythmias. Maintenance of normal sinus rhythm in patients with highly symptomatic atrial fibrillation or atrial flutter (AFIB/AFL) who are currently in sinus rhythm.
Limitations Of use:
Use in less severe arrhythmias even if symptomatic is not recommended. Avoid in asymptomatic ventricular premature contractions. Paroxysmal atrial fibrillation where AFIB/AFL is easily reversed (eg, Valsalva maneuver): not recommended.
Initiate only in appropriate clinical setting that can provide cardiac resuscitation, continuous ECG, and creatinine clearance monitoring. Perform baseline ECG and calculate creatinine clearance. Ventricular arrhythmia: if QT <450msec and CrCl >60mL/min: initially 80mg twice daily. Renal impairment: (CrCl 40–60mL/min): initially 80mg once daily; (CrCl <40mL/min): not recommended. May increase in increments of 80mg/day every 3 days as needed, provided QT <500msec. Usual range 80–160mg once or twice daily; refractory patients may need 240–320mg once or twice daily. AFIB/AFL: if QT <450msec and CrCl >60mL/min: initially 80mg twice daily. Renal impairment: (CrCl 40–60mL/min): initially 80mg once daily; (CrCl <40mL/min): not recommended. If inadequate response and is tolerated with QT <520msec, may Increase at 3-day intervals to 160mg once or twice daily.
Initiate only in appropriate clinical setting that can provide cardiac resuscitation, continuous ECG, and creatinine clearance monitoring. Perform baseline ECG and calculate creatinine clearance. Ventricular arrhythmia: <2yrs: see full labeling for dose reductions. ≥2yrs: 30mg/m2 three times daily (90mg/m2 total daily dose). May titrate to max 60mg/m2. Allow at least 36hrs between dose increments to attain steady-state concentration.
Sinus bradycardia (<50bpm). Sick sinus syndrome. 2nd or 3rd degree AV block, unless paced. Baseline QT interval >450msec. Long QT syndromes. Cardiogenic shock. Uncontrolled heart failure. Renal impairment (CrCl <40mL/min). Hypokalemia (<4mEq/L). Asthma.
Life-threatening proarrhythmia. Should be hospitalized in a facility that can provide cardiac resuscitation, continuous ECG monitoring, and calculations of creatinine clearance. Do not start if baseline QTc >450msec; if QT prolongs ≥500msec, reduce dose, increase dosing interval, or discontinue.
Increased arrhythmia risk in females, renal impairment, excessive QTc prolongation, history of cardiomegaly or CHF, sustained ventricular tachycardia, electrolyte disturbances, or with high doses of sotalol. Monitor QT interval after each dose during initiation and titration. Correct electrolyte imbalances (esp. hypokalemia, hypomagnesemia) before starting. Monitor hemodynamics in those with marginal cardiac compensation. Acid-base imbalance. CHF. Recent acute MI. Bronchospastic diseases. Diabetes. Hyperthyroidism. History of anaphylaxis. Surgery. Avoid abrupt cessation (withdraw over 1–2 weeks if possible, monitor for angina and acute coronary insufficiency). Pregnancy (Cat.B). Nursing mothers: not recommended.
Class II and III antiarrhythmic.
Class IA antiarrhythmics (eg, disopyramide, quinidine, procainamide), Class III antiarrhythmics (eg, amiodarone), or other drugs that prolong QT interval (eg, some phenothiazines, tricyclic antidepressants, certain oral macrolides or quinolones): not recommended. Withhold Class I and III antiarrhythmics for at least 3 half-lives before starting. Caution with Class IB and IC antiarrhythmics. Additive conduction abnormalities and hypotension with digoxin, β-blockers, calcium channel blockers. Hypotension, bradycardia with reserpine, guanethidine, other catecholamine-depleting drugs. Increased rebound hypertension when withdrawing clonidine. Diuretics (monitor electrolytes). Antagonizes albuterol, terbutaline, isoproterenol, other β-agonists. Monitor antidiabetic agents. May block epinephrine. Avoid within 2 hours of aluminum- or magnesium-containing antacids.
Fatigue, bradycardia, dizziness, headache, dyspnea, nausea, vomiting, diarrhea; QT prolongation, Torsade de Pointes, hypotension (monitor).
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Congress Passes Bill to Fight Opioid Crisis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure